Clinical Trial Update: Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the efficacy and safety of bortezomib as first-line treatment for acquired thrombotic thrombocytopenic purpura (TTP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura Acquired

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Thrombotic Thrombocytopenic Purpura, Acquired | Phase 4 | Status: UNKNOWN